LEXX News and Press, Lexaria Bioscience Corp. From 11/27/23

2023-11-27 12:12:40 ET More on Lexaria Bioscience Corp. Lexaria Bioscience enters license agreement with SulfoSyn Lexaria Bioscience enters into securities purchase agreement Seeking Alpha’s Quant Rating on Lexaria Bioscience Corp. Historical earnings ...

2023-11-27 10:50:10 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employ...

(TheNewswire) DehydraTECH TM -powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus ® : Sustained higher levels of semaglutide in blood; Faster achievement of peak drug delivery; and Reduced side effe...

Lexaria Bioscience Corp. (LEXX) is expected to report $-0.17 for Q4 2023

Lexaria, a global innovator in drug delivery platforms, has, since 2014, continuously worked on its patented DehydraTECH(TM) drug delivery technology The technology has demonstrated overall effectiveness in enhanced delivery of fat-soluble molecules through the human gastrointestinal system, as...

Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for a growing range of applications including oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and more. Through previous ...

Lexaria, a global innovator in drug delivery platforms, is exploring the impact of its patented DehydraTECH(TM) technology on the oral performance of GLP-1 drugs for potential diabetes and weight loss treatment The company hopes to make these drugs more effective with reduced side effects, and ...

Lexaria, a global innovator in drug delivery platforms, recently announced plans to launch new human and animal studies examining whether its patented DehydraTECH(TM) technology can make GLP-1 drugs better Lexaria has previously demonstrated DehydraTECH’s overall potential in its DIAB-A2...

Lexaria (NASDAQ: LEXX) , a global innovator in drug delivery platforms, remains on track to submit an Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial HYPER H23-1. “Lexaria’s IND submission builds on five previous h...

2023-11-01 08:30:58 ET NetworkNewsWire Editorial Coverage New York, NY – November 1, 2023 – GLP-1 agonists have become incredibly popular obesity drugs, reshaping the standard of care as people increasingly turn to the new class of drugs in lieu of conventional...